Clair Health, a women’s health technology company founded by Stanford graduates Jenny Duan and Abhinav Agarwal, has secured $11.6 million in funding to support the development and launch of a noninvasive wearable designed to provide continuous hormone insights. The company plans to launch its wrist-worn device and companion app in November 2026 and reports that more than 25,000 individuals have joined its waitlist.
The company’s approach differs from traditional hormone testing methods. Rather than directly measuring hormone levels through blood, saliva or urine samples, Clair uses machine learning models to infer hormonal activity from physiological signals collected by wearable sensors. Data points including skin temperature, heart rate, sleep patterns and breathing metrics are analyzed to estimate levels of estrogen, progesterone, luteinizing hormone (LH) and follicle-stimulating hormone (FSH).
According to Clair, the wearable incorporates 10 biosensors and evaluates more than 130 proprietary biomarkers to generate personalized hormone-related insights. The company says early beta testing has enabled identification of nine distinct sub-phases of the female hormone cycle, compared with the four phases commonly referenced in educational materials and consumer health applications.
The concept originated from Duan’s personal experience with irregular menstrual cycles and the limitations she encountered using conventional period-tracking applications. While studying symbolic systems with a focus on AI ethics at Stanford, she and Agarwal began exploring how existing wearable data streams could be interpreted through a hormonal health framework.
Industry observers note that the company enters a growing market for women’s health technologies. Unlike competitors that rely on direct hormone measurement through saliva-based testing, Clair’s platform is built around continuous inference models designed to deliver insights through a device users can wear daily.
Commenting on the company’s vision, Emily Bennett, Partner at a16z speedrun, said, “Clair represents a generational shift in women's health, moving from guesswork and episodic testing to continuous, real time hormone intelligence that can inform daily decisions.”
Dr. Emily Kraus, a Clair Health advisor, added, “As a sports medicine physician and scientist focused on female athlete health, I see a major need for better tools that help women understand how hormonal patterns may relate to training, recovery, symptoms, and performance across the lifespan.”
To support scientific validation, Clair plans to conduct an independent clinical trial through Stanford’s Gladstone BeeHive program and publish peer-reviewed results evaluating the performance of its hormone inference technology.
Click here for the original news story.
